These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7397945)

  • 1. Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.
    Andersson B; Beran M
    Cancer Chemother Pharmacol; 1980; 4(3):205-7. PubMed ID: 7397945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.
    Andersson B; Andersson I; Beran M; Ehrsson H; Eksborg S
    Cancer Chemother Pharmacol; 1979; 2(1):15-7. PubMed ID: 498413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.
    Nilsson SO; Andersson B; Eksborg S; Beran M; Ehrsson H
    Cancer Chemother Pharmacol; 1981; 5(4):261-6. PubMed ID: 7261253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPLC determination of daunorubicin and daunorubicinol in human plasma.
    Hulhoven R; Desager JP
    Biomedicine; 1977 Apr; 27(3):102-4. PubMed ID: 890014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia.
    Paul C; Baurain R; Gahrton G; Peterson C
    Cancer Lett; 1980 Jun; 9(4):263-9. PubMed ID: 6930988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients.
    Eksborg S; Ehrsson H; Andersson B; Beran M
    J Chromatogr; 1978 Jun; 153(1):211-8. PubMed ID: 659557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.
    Hulhoven R; Sokal G; Harvengt C
    Cancer Chemother Pharmacol; 1979; 3(4):243-7. PubMed ID: 535134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake and metabolism of daunorubicin by human leukemia cells.
    DeGregorio MW; Carrera CJ; Klock JC; Wilbur JR
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):29-32. PubMed ID: 6961971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.
    Paul C; Tidefelt U; Liliemark J; Peterson C
    Leuk Res; 1989; 13(2):191-6. PubMed ID: 2927175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia.
    Paul C; Liliemark J; Tidefelt U; Gahrton G; Peterson C
    Ther Drug Monit; 1989; 11(2):140-8. PubMed ID: 2718219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography.
    Andersson B; Beran M; Eberhardsson B; Eksborg S; Slanina P
    Cancer Chemother Pharmacol; 1979; 2(3):159-67. PubMed ID: 110487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia.
    DeGregorio MW; Carrera CJ; Klock JC; Pegelow CH; Wilbur JR
    Cancer Treat Rep; 1982 Dec; 66(12):2085-8. PubMed ID: 6958366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.
    Paul C; Peterson C; Gahrton G; Lockner D
    Cancer Chemother Pharmacol; 1979; 2(1):49-52. PubMed ID: 498420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.
    Gessner T; Preisler HD; Azarnia N; Bolanowska W; Vogler WR; Grunwald H; Joyce R; Goldberg J
    Med Oncol Tumor Pharmacother; 1987; 4(1):23-31. PubMed ID: 3600054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin.
    Speth PA; van de Loo FA; Linssen PC; Wessels HM; Haanen C
    Clin Pharmacol Ther; 1986 Dec; 40(6):643-9. PubMed ID: 3465490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daunorubicin, daunorubicinol and DNA plasma kinetics after I.V. administration of daunorubican-DNA complex in the rabbit.
    Hulhoven R
    Biomedicine; 1978 Jul; 29(5):164-7. PubMed ID: 719130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.
    Trillet V; Lakhal M; Lang J; Perrin-Fayolle E; Timour Chah Q; Fière D; Faucon G
    Eur J Clin Pharmacol; 1985; 29(1):127-9. PubMed ID: 4054202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.